Will Guidant Return To Pharma Roots After 10 Years As Stand-Alone Entity?
This article was originally published in The Gray Sheet
Executive Summary
Guidant's cardiac surgery device and guiding catheter segments offer an attractive fit with Johnson & Johnson, though ICD market access and drug-eluting stent synergies would be the true drivers of any merger